Septerna (SEPN) announced its decision to discontinue the Phase 1 single- and multiple-ascending dose clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of ...

If you have not heard of Havid Nagan, it is about time you did. F.P.Journe alumnus Aren Bazerkanian founded the brand in 2022, and he is doing things properly. Despite barely three years of the ...